(2007-Scarpellini)High dosage rifaximin for the treatment of small intestinal bacterial overgrowth.pdf

下载文档

3
0
约2.04万字
约 6页
2017-04-13 发布于江苏
举报
版权申诉
保障服务

(2007-Scarpellini)High dosage rifaximin for the treatment of small intestinal bacterial overgrowth.pdf

1、本文档共6页，可阅读全部内容。
2、有哪些信誉好的足球投注网站（book118）网站文档一经付费（服务费），不意味着购买了该文档的版权，仅供个人/单位学习、研究之用，不得用于商业用途，未经授权，严禁复制、发行、汇编、翻译或者网络传播等，侵权必究。
3、本站所有内容均由合作方或网友上传，本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺！文档内容仅供研究参考，付费前请自行鉴别。如您付费，意味着您自己接受本站规则且自行承担风险，本站不退款、不进行额外附加服务；查看《如何避免下载的几个坑》。如果您已付费下载过本站文档，您可以点击这里二次下载。
4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等，请点击“版权申诉”（推荐），也可以打举报电话：400-050-0827(电话支持时间：9:00-18:30)。

(2007-Scarpellini)High dosage rifaximin for the treatment of small intestinal bacterial overgrowth

High dosage rifaximin for the treatment of small intestinal bacterial overgrowth E. SCARPELLINI , M. GABRIELLI , C . E . LAURITANO, A. LUPASCU, G. MERRA, G. CAMMAROTA, I . A . CAZZATO, G. GASBARRINI A. GASBARRINI Internal Medicine Department, Gemelli Hospital, Catholic University of Sacred Heart, Rome, Italy Correspondence to: Dr. A. Gasbarrini, Internal Medicine and Angiology, Catholic University of Sacred Heart, Gemelli Hospital, Largo A. Gemelli, 8; 00168 Rome, Italy. E-mail: angiologia@rm.unicatt.it Publication data Submitted 12 October 2006 First decision 30 October 2006 Resubmitted 3 January 2007 Accepted 15 January 2007 SUMMARY Background Rifaximin is a broad spectrum non-absorbable antibiotic used for treat- ment of small intestinal bacterial overgrowth. Doses of 1200 mg ?day showed a decontamination rate of 60% with low side-effects incidence. Aims To assess efficacy, safety and tolerability of rifaximin 1600 mg with respect to 1200 mg ?day for small intestinal bacterial overgrowth treat- ment. Methods Eighty consecutive small intestinal bacterial overgrowth patients were enrolled. Diagnosis of small intestinal bacterial overgrowth based the clinical history and positivity to H2 ?CH4 glucose breath test. Patients were randomized in two 7-day treatment groups: rifaximin 1600 mg (group 1); rifaximin 1200 mg (group 2). Glucose breath test was reas- sessed 1 month after. Compliance and side-effect incidence were also evaluated. Results One drop-out was observed in group 1 and two in group 2. Glucose breath test normalization rate was significantly higher in group 1 with respect to group 2 both in intention-to-treat (80% vs. 58%; P 0.05) and per protocol analysis (82% vs. 61%; P 0.05). No significant differ- ences in patient compliance and incidence of side effects were found between groups. Conclusions Rifaximin 1600 mg ?day showed a significantly higher efficacy for small intestinal bacterial overgrowth treatment with respect to 1200 mg with similar complia